The etiology of liver damage imparts cytokines transforming growth factor β1 or interleukin-13 as driving forces in fibrogenesis

Hepatology

Volumn 50, Issue 1, 2009, Pages 230-243

  Weng, Hong Lei ^a,d   Liu, Yan ^a   Chen, Jia Lin ^e   Huang, Tong ^f   Xu, Li Jun ^g   Godoy, Patricio ^a   Hu, Jun Hua ^a   Zhou, Cheng ^d   Stickel, Felix ^h   Marx, Alexander ^b   Bohle, Rainer M ⁱ   Zimmer, Vincent ⁱ   Lammert, Frank ⁱ   Mueller, Sebastian ^c   Gigou, Michelle ^j   Samuel, Didier ^j   Mertens, Peter R ^k   Singer, Manfred V ^a   Seitz, Helmut K ^c   Dooley, Steven ^a  

^a Department of Medicine II   (Germany)

^b Department of Pathology   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e JIAXING UNIVERSITY   (China)

^f Zhenhai Lianhua Hospital   (China)

^g FUJIAN MEDICAL UNIVERSITY   (China)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ SAARLAND UNIVERSITY   (Germany)

^j INSERM   (France)

^k OTTO VON GUERICKE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; INTERLEUKIN 13; SMAD2 PROTEIN; STAT6 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHISTOSOMIASIS JAPONICA; SIGNAL TRANSDUCTION; STEATOSIS; IN VITRO STUDY; LIVER CIRRHOSIS; LIVER DISEASE; PHYSIOLOGY;

HUMANS; INTERLEUKIN-13; LIVER CIRRHOSIS; LIVER DISEASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 67651165609     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22934     Document Type: Article

References (45)

1. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539-548.
2. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-2250.
3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
4. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003;38(Suppl 1):S38-S53.
5. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002;7:d793-d807.
6. Weng HL, Ciuclan L, Liu Y, Hamzavi J, Godoy P, Gaitantzi H, et al. Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. HEPATOLOGY 2007;46:1257-1270. (Pubitemid 350144790)
7. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, et al. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008;135: 642-659.
8. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008;88:112-123. (Pubitemid 351161272)
9. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337-23347. (Pubitemid 47311952)
10. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol 2005;11:3260-3263. (Pubitemid 40973896)
11. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. HEPATOLOGY 2006;43:771-779.
12. Stickel F, Urbaschek R, Schuppan D, Poeschl G, Oesterling C, Conradt C, et al. Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci 2001;46:2025-2032. (Pubitemid 32844173)
13. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700. (Pubitemid 36724933)
14. Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S. TGF-beta/Smad signaling in the injured liver. Z Gastroenterol 2006;44:57-66.
15. Alves Oliveira LF, Moreno EC, Gazzinelli G, Martins-Filho OA, Silveira AM, Gazzinelli A, et al. Cytokine production associated with periportal fibrosis during chronic schistosomiasis mansoni in humans. Infect Immun 2006;74:1215-1221. (Pubitemid 43185561)
16. Bartley PB, Ramm GA, Jones MK, Ruddell RG, Li Y, McManus DP. A contributory role for activated hepatic stellate cells in the dynamics of Schistosoma japonicum egg-induced fibrosis. Int J Parasitol 2006;36:993-1001. (Pubitemid 44107933)
17. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003;21:425-456.
18. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4:583-594.
19. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
20. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 2000;164:2585-2591.
21. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001;194:809-821. (Pubitemid 32983016)
22. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 2004;173:4020-4029. (Pubitemid 39280766)
23. Schäfer S, Zerbe O, Gressner AM. The synthesis of proteoglycans in fatstoring cells of rat liver. HEPATOLOGY 1987;7:680-687. (Pubitemid 17130709)
24. Greenwel P, Rubin J, Schwartz M, Hertzberg EL, Rojkind M. Liver fat storing cell clones obtained from a CCl4-cirrhotic rat are heterogeneous with regard to proliferation, expression of extracellular matrix components, interleukin-6, and connexin-43. Lab Invest 1993;69:210-216. (Pubitemid 23262501)
25. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
26. Lee DK, Park SH, Yi Y, Choi SG, Lee C, Parks WT, et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev 2001;15:455-466. (Pubitemid 32187006)
27. Yoo YD, Ueda H, Park K, Flanders KC, Lee YI, Jay G, et al. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest 1996;97:388-395. (Pubitemid 26039402)
28. McClary H, Koch R, Chisari FV, Guidotti LG. Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med 2000;192:289-294. (Pubitemid 30470311)
29. Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA. IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 1999;162:920-930.
30. Uemura M, Swenson ES, Gaca MD, Giordano FJ, Reiss M, Wells RG. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and {alpha}-smooth muscle actin organization. Mol Biol Cell 2005;16:4214-4224. (Pubitemid 41262890)
31. Chen A. Acetaldehyde stimulates the activation of latent transforming growth factor-beta1 and induces expression of the type II receptor of the cytokine in rat cultured hepatic stellate cells. Biochem J 2002;368:683-693. (Pubitemid 36042670)
32. Anania FA, Potter JJ, Rennie-Tankersley L, Mezey E. Activation by acetaldehyde of the promoter of the mouse alpha2(I) collagen gene when transfected into rat activated stellate cells. Arch Biochem Biophys 1996; 331:187-193.
33. Roulot D, Durand H, Coste T, Rautureau J, Strosberg AD, Benarous R, et al. Quantitative analysis of transforming growth factor beta1 messenger RNAin the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. HEPATOLOGY 1995;21:298-305.
34. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. HEPATOLOGY 2007;46:48-57. (Pubitemid 47171920)
35. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, Shiratori Y, et al. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol 2004;72:52-59. (Pubitemid 37484743)
36. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004;126:529-540. (Pubitemid 38182310)
37. Murata T, Ohshima T, Yamaji M, Hosaka M, Miyanari Y, Hijikata M, et al. Suppression of hepatitis C virus replicon by TGF-beta. Virology 2005;331:407-417. (Pubitemid 40075466)
38. Choi SH, Hwang SB. Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. J Biol Chem 2006;281:7468-7478.
39. Mola PW, Farah IO, Kariuki TM, Nyindo M, Blanton RE, King CL. Cytokine control of the granulomatous response in Schistosoma mansoni-infected baboons: role of exposure and treatment. Infect Immun 1999;67:6565-6571.
40. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med 2003;198:1179-1188. (Pubitemid 37323383)
41. Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD, Wynn TA. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. HEPATOLOGY 2001;34:273-282.
42. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999;104:777-785.
43. Booth M, Mwatha JK, Joseph S, Jones FM, Kadzo H, Ireri E, et al. Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Immunol 2004;172:1295-1303. (Pubitemid 38113793)
44. Sugimoto R, Enjoji M, Nakamuta M, Ohta S, Kohjima M, Fukushima M, et al. Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells. Liver Int 2005;25:420-428. (Pubitemid 40500578)
45. Thompson RW, Pesce JT, Ramalingam T, Wilson MS, White S, Cheever AW, et al. Cationic amino acid transporter-2 regulates immunity by modulating arginase activity. PLoS Pathog 2008;4:e1000023. (Pubitemid 351631095)